Immix Biopharma Investor Presentation Deck
NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient
Population
Newly Diagnosed
Newly diagnosed
US Incidence
-4,000
Johnson & Johnson
DARZALEX
(daratumumab)
S
00 mm 400 mg/20 m
Darzalex Combination
(combined with
cyclophosphamide, bortezomib,
and/or dexamethasone)
Weekly treatments
prothena
NASDAQ:PRTA
Birtamimab
(combined with Darzalex,
cyclophosphamide, bortezomib,
and/or dexamethasone)
AstraZeneca
CAELUM
BIOSCIENCES
CAEL-101
Mayo Stage
IIIb only
Weekly treatments
(combined with Darzalex,
cyclophosphamide,
bortezomib, and/or
dexamethasone)
Relapsed/Refractory -3,040
Relapsed/Refractory
Estimated relapsed/refractory US
Prevalence -29,712 in 2023
(Previously Treated)
Eligible R/R ALA Patients ~32,752
NXC-201-100% ORR
One-time treatment | Monotherapy | All Relapsed/Refractory ALA Patients
32,752 Eligible U.S. AL Amyloidosis Patients
No FDA Approved Drugs in Relapsed/Refractory AL Amyloidosis
●●●
S
IMMİX
BIOPHARMA
Note: Public information development plans as of 2023. Dara-CyBorD: Daratumumab, Bortezomib + cyclophosphamide + dexamethasone. BMD: bortezomib, melphalan, and dexamethasone. Source: Dima D, et al. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of
Therapeutic Innovation. JCO Oncol Pract, 2023; Jimenez-Zepeda VH, et al. Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort study. EJHaem. 2022; Bou Zerdan M, et al. Systemic AL
amyloidosis: current approach and future direction. Oncotarget. 2023; Kumar S, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; Browning S, et al. Hematologic relapse 21
AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood. 2017; Palladini G, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018; Staron A, et al. Marked progress in AL
amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(8):139; Lu R, Richards TA. AL Amyloidosis: Unfolding a Complex Disease. J Adv Pract Oncol. 2019;10(8):813-825.View entire presentation